Source-grounded facts extracted from QHSLab, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
QHSLab, Inc. terminated Repurchase Agreement with MedScience Research Group, Inc..
“QHSLab, Inc. (the “Company”) consummated a Note Repurchase Agreement (the “Repurchase Agreement”) with MedScience Research Group, Inc., a Florida corporation (“MedScience”).”
QHSLab, Inc. amended Promissory Note Modification and Partial Conversion Agreement with Alex Mirakian MD PA (effective 2025-12-31).
“On December 31, 2025, QHSLab, Inc., (the Company), entered into a Promissory Note Modification and Partial Conversion Agreement (the Modification Agreement) with Alex Mirakian MD PA (the Holder), in connection with a previously issued convertible promissory note dated May 7, 2021 (the Original Note).”
QHSLab, Inc. entered into Subscription Agreements with two accredited investors valued at approximately $500,000 (effective 2025-12-26).
“On December 26, 2025, QHSLab, Inc. (the “Company”) accepted subscription agreements from two accredited investors for the purchase of approximately $500,000 of the Company’s common stock and warrants”
QHSLab, Inc. reported a default on convertible notes of in excess of $1.4 million at 18 percent per annum.
“The Notes, which had been in default and bore interest at a default rate of 18 percent per annum, had an aggregate outstanding balance consisting of principal and accrued interest in excess of $1.4 million as of the date of redemption.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.